BioHarvest Sciences says it has successfully scaled its cannabis cells with trichomes production by a factor of 250 times and it is now growing them in medium-scale bioreactors

BioHarvest Sciences Inc. said it has successfully scaled its Cannabis cells with trichomes production by a factor of 250 times and it is now growing cannabis in medium-scale bioreactors, paving the way for its next scale-up milestone, where it will reach industrial-scale production. 

The next milestone, combined with the drying and measurement standards being concurrently developed, would constitute the successful completion of the company’s cannabis development program.

In a statement, BioHarvest Sciences CEO, Ilan Sobel, said: ”Our industry-leading plant cell biology team is on track to deliver on one of the most challenging plant biological missions of growing cells of Cannabis Trichomes in liquid media at an industrial scale. Completing this mission will pave the way to the commercialization of BioFarming based Cannabis and Hemp products, marking a major turning point for the mainstream adoption of Cannabis by the global food and health sectors. The ability to economically and sustainably produce consistent, clean and pure whole spectrum Cannabis is nothing short of a revolution for the industry.”

READ: BioHarvest Sciences unveils groundbreaking cannabis trichome structure

Moving to the medium-scale bioreactors stage is not only a critical milestone in the scale-up and the proof of the capability of the BioFarming technology to produce cannabis biomass, but is also an integral part of the industrial process development itself, the company said. The next milestone of the development program is growing cannabis trichomes in industrial size bioreactors, it added.

Dr Yochi Hagay, BioHarvest Sciences CTO noted: ”The R&D methodology and relentless efforts are paying off. We are happy to have reached such a critical milestone. The recently announced and proprietary development of the Amalgamated Trichomes Coral Structure (ATCS) has certainly enabled this scale-up progress.

“As described before, ATCS protects the Trichomes during the growth phase against the shear forces generated by the media fluid motion. Such motion is exacerbated as you increase the size of the bioreactor, and I am confident that ATCS will sustain the forces in the next size of bioreactors, which is the final industrial-scale step. I look forward to announcing the completion of the whole program soon.”

And Eitan Popper, chairman of BioHarvest Science’ board of advisors and former president and oo-founder of MedReleaf added: ”BHSC’s R&D team is making meaningful progress every month in the commercial scale-up of their Cannabis production. It is important to note that the most challenging part of the scale-up process is the transition from lab/bench scale to small-scale bioreactors, and then to medium-scale bioreactors. We are eagerly looking forward to the next Cannabis milestone announcement, as we know that it will be meaningful.”

Based in Vancouver British Columbia, BioHarvest Sciences is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing active plant ingredients without the necessity to grow the plant itself.

The company’s technology is non-GMO and has already been validated by VINIA, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences. The company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA and other Super Fruit Nutraceutical products.

Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences’ objective is to become a leading supplier of cannabis for both medicinal and legal recreational use.

Contact the author at [email protected]

Story by ProactiveInvestors